Loading...
Selexipag in the management of pulmonary arterial hypertension: an update
Selexipag is a compound that was designed to overcome the issues associated with oral administration of prostanoid compounds, beraprost and treprostinil in the treatment of pulmonary hypertension (PAH). As a selective IP agonist, it was designed to avoid the off-target prostanoid effects especially...
Na minha lista:
| Udgivet i: | Drug Healthc Patient Saf |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6689562/ https://ncbi.nlm.nih.gov/pubmed/31496830 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DHPS.S181313 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|